×
Please click
here
if you are not redirected within a few seconds.
All
News
Maps
Images
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
VYNE Therapeutics receives FDA approval for trial of VYN202
Clinical Trials Arena
VYNE Therapeutics has received US Food and Drug Administration clearance for its investigational new drug (IND) application for VYN202.
4 weeks ago
Vyne Therapeutics Inc's New Natural and Human Disruptions Risk – A Cause for Worry? - TipRanks.com
Tipranks
Vyne Therapeutics Inc (VYNE) has disclosed a new risk, in the Natural and Human Disruptions category. Vyne Therapeutics Inc. faces long-term business risks...
3 months ago
VYNE Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
Yahoo Finance
VYNE Therapeutics ( NASDAQ:VYNE ) Full Year 2023 Results Key Financial Results Net loss: US$27.9m (loss narrowed by 18...
3 months ago
Here's Why We're Watching VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Situation
Simply Wall Street
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price.
1 month ago
VYNE Stock Quote Price and Forecast
CNN
VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. It develops and commercializes solutions using its proprietary Molecule...
7 months ago
Thinking about buying stock in Coherus Biosciences, Vyne Therapeutics, Intuitive Machines, SoFi Technologies, or ...
NewsChannel 34
NEW YORK, Oct. 30, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CHRS, VYNE, LUNR, SOFI, and CYBN.
7 months ago
VYNE Therapeutics'(NASDAQ:VYNE) Share Price Is Down 11% Over The Past Year.
Yahoo Movies UK
Investors can approximate the average market return by buying an index fund. But if you buy individual stocks, you can...
1 month ago
Tay Therapeutics, VYNE sign licensing deal for oral BET inhibitor
Pharmaceutical Technology
Tay Therapeutics has signed a licensing deal with VYNE Therapeutics for the development of its oral BET inhibitor.
13 months ago
Journey of Vyne's topical drugs continues with $20M deal
Fierce Pharma
Journey Medical is taking control of a topical drug delivery platform and three drugs based on the technology. The dermatology specialist is...
28 months ago
VYNE and Tay Therapeutics reach licence agreement
PharmaTimes
Deal involves an oral BET inhibitor which treats fibrotic and immuno-inflammatory disorders. University of Dundee-based Tay Therapeutics – a...
13 months ago